Clinical Trials Browser

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT05982522 2025-04-30

IN10018 Combination Therapy in Previously-treated Solid Tumors

Phase 1/2 Not yet recruiting

72 enrolled

Other solid neoplasm

Solid Tumor

NCT06030258 2025-04-30

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Phase 1/2 Recruiting

120 enrolled

Thoracic

Small Cell Lung Cancer Extensive Stage

NCT04666688 2025-02-12

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Completed

44 enrolled

GastrointestinalGenitourinaryHead & Neck

Bile Duct Neoplasms, Carcinoma, Transitional Cell, Colonic Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05431270 2025-01-31

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Phase 1/2 Recruiting

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04276493 2024-12-06

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Phase 1/2 Completed

71 enrolled

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT03379259 2024-10-26

Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1/2 Terminated

39 enrolled 29 charts

Other solid neoplasm

Advanced Solid Tumors

NCT03941873 2024-10-26

A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

Phase 1/2 Completed

111 enrolled 22 charts

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular

NCT04068519 2024-10-26

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

Phase 1/2 Completed

300 enrolled 23 charts

Other solid neoplasm

Advanced Solid Tumors

NCT06471673 2024-08-26

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Phase 1/2 Recruiting

18 enrolled

Breast

Breast Neoplasms

NCT05906524 2024-01-10

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

Phase 1/2 Unknown

85 enrolled

Other solid neoplasm

Advanced HCC

NCT05840835 2023-08-08

IMMINENT-01

Phase 1/2 Unknown

60 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT04813107 2022-02-22

ANTICIPATE

Phase 1/2 Unknown

79 enrolled

Genitourinary

Muscle Invasive Bladder Cancer

Clinical Trials

KontRASt-01

KontRASt-R

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

TOUCH

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

IN10018 Combination Therapy in Previously-treated Solid Tumors

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors

A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

IMMINENT-01

ANTICIPATE